Bone Abstracts

Objective: The study evaluated the efficacy of the therapeutic compliance in brittle bone disease applied to frail elderly people affected by osteoporosis and in treatment with Denosumab.

Methods: We studied people ≥75; 43 women (mean age 83±3) and 14 men (mean age 85±3), all suffering from femoral osteoporosis T-score <−4. In 34 women and 6 men, we discovered 1–2 vertebral fractures. They have been treated with Denosumab 60 mg in a 6-month span of time and Colecalciferolo 50,000 UI every 30 days. The study design included at T0-T24-T48.

Results: At T0 we considered: i) Geriatric Depression State: mild depression 40.5% P<0.05, severe depression 53.6% P<0.05; ii) Numerical Rating Scale: moderate pain 25.6% P<0.01, severe pain 74.4% P<0.01; iii) Tinetti balance and gait Scale: mean score 10 (high risk of fall) 83.8% P<0.5; mean score 1(non walking) 16.2% P<0.5. Finally at T 48 we detected: i) Geriatric Depression State: mild depression 69.3% P<0.05, severe depression 24.7% P<0.05; ii) Numerical Rating Scale: mild pain 37.3% P<0.01, moderate pain 28.1% P<0.01, severe pain 9.5% P<0.01; iii) Tinetti balance and gait Scale: mean score 21 (low risk of fall) 86.5% P<0.5, mean score 10.7 (high risk of fall) 7.6%. At T0 we detected: MMSE mean score 19.5; mean comorbidity index 3; mean severity index of comorbidity 2.23. Between T24 and T48, through X rays of the spine in the dorsal, lumbar and sacral regions, we checked that no new fractures had occurred. At T48 the DEXA Bone Densitometry showed a mean femoral T-score −2.9.

Conclusion: We evaluated the frailty markers (depression, pain, fall) and, after the Denosumab treatment, the efficacy of the therapeutic compliance compared to the changes of the scores and to the quality of life’s improvement.